Genmab Submits Protocol Amendment For Ofatumumab Phase 3 Head-to-head Study NASDAQ According to the amended protocol all patients recruited in the study which investigates ofatumumab plus chemotherapy versus rituximab plus chemotherapy in relapsed or refractory DLBCL, will receive the same chemotherapy regimen. |
